Targeting Carnitine Biosynthesis: Discovery of New Inhibitors against γ-Butyrobetaine Hydroxylase
作者:Kaspars Tars、Janis Leitans、Andris Kazaks、Diana Zelencova、Edgars Liepinsh、Janis Kuka、Marina Makrecka、Daina Lola、Viktors Andrianovs、Daina Gustina、Solveiga Grinberga、Edvards Liepinsh、Ivars Kalvinsh、Maija Dambrova、Einars Loza、Osvalds Pugovics
DOI:10.1021/jm401603e
日期:2014.3.27
γ-Butyrobetaine hydroxylase (BBOX) catalyzes the conversion of gamma butyrobetaine (GBB) to l-carnitine, which is involved in the generation of metabolic energy from long-chain fatty acids. BBOX inhibitor 3-(1,1,1-trimethylhydrazin-1-ium-2-yl)propanoate (mildronate), which is an approved, clinically used cardioprotective drug, is a relatively poor BBOX inhibitor and requires high daily doses. In this
γ-丁甜菜碱羟化酶(BBOX)催化将γ-丁甜菜碱(GBB)转化为1-肉碱,这涉及从长链脂肪酸产生代谢能。BBOX抑制剂3-(1,1,1-三甲基肼-1-鎓-2-基)丙酸酯(mildronate)是一种批准的,临床上使用的心脏保护药物,是一种相对较差的BBOX抑制剂,需要每天高剂量。在本文中,我们描述了51种化合物的设计,合成和性质,其中包括GBB和次膦酸酯类似物。我们发现了具有改进的IC 50的新型BBOX抑制剂价值观 最好的例子是在纳摩尔范围内,与次膦酸盐相比,大约好2个数量级。对于六种抑制剂,已经解决了与BBOX形成复合物的晶体结构,以解释其活性并为进一步的抑制剂设计铺平了道路。